

Ozempic[®] (semaglutide) – New indication; Rybelsus[®] (semaglutide) – Label update

- On January 16, 2020, [Novo Nordisk announced the FDA approval of Ozempic \(semaglutide\) injection](#), to reduce the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease.
 - Ozempic has not been studied in patients with a history of pancreatitis. Other antidiabetic therapies should be considered in patients with a history of pancreatitis.
 - Ozempic is not a substitute for insulin. Ozempic is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.
- Ozempic is also approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.
- The approval of Ozempic for the new indication was based on SUSTAIN 6, a placebo-controlled, double-blind, cardiovascular outcomes study in 3,297 patients with inadequately controlled T2DM and atherosclerotic CV disease. Patients were randomized to Ozempic (0.5 mg or 1 mg) once weekly or placebo for a minimum observation time of 2 years. The primary endpoint, MACE, was the time to first occurrence of a three-part composite outcome which included CV death, non-fatal myocardial infarction and non-fatal stroke.
 - Ozempic significantly reduced the occurrence of MACE. The estimated hazard ratio (HR) for time to first MACE was 0.74 (95% CI: 0.58, 0.95).
- In addition, the label for oral semaglutide ([Rybelsus[®]](#)) was [updated](#) to include clinical data from PIONEER 6, a placebo-controlled, double-blind study in 3,183 patients with inadequately controlled T2DM and atherosclerotic CV disease. Patients were randomized to Rybelsus 14 mg once daily or placebo for a median observation time of 16 months. The same three-part MACE outcome was used as the primary endpoint.
 - Rybelsus demonstrated non-inferiority to placebo (HR 0.79, 95% CI: 0.57, 1.11) over the median observation time of 16-months.
- In June 2019, Novo Nordisk initiated the SOUL CVOT in 9,642 adults with T2DM and established CV disease to further evaluate the CV effect of Rybelsus.
- Ozempic and Rybelsus carry a boxed warning for risk of thyroid C-cell tumors.
- The recommended starting dose of Ozempic for all T2DM patients is 0.25 mg subcutaneously once weekly for 4 weeks. The 0.25 mg dose is intended for treatment initiation and is not effective for glycemic control. After 4 weeks on the 0.25 mg dose, the dosage should be increased to 0.5 mg once weekly.
 - If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose, the dosage may be increased to 1 mg once weekly. The maximum recommended dosage is 1 mg once weekly.
- The recommended starting dose of Rybelsus for all T2DM patients is 3 mg once daily for 30 days. The 3 mg dose is intended for treatment initiation and is not effective for glycemic control. After 30 days on the 3 mg dose, the dose should be increased to 7 mg once daily.

- The dose may be increased to 14 mg once daily if additional glycemic control is needed after at least 30 days on the 7 mg dose.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.